Individual research recommendation details

Recommendation ID

NG217/02

Question

Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated?

Any explanatory notes
(if applicable)

For a short explanation of why the committee made this recommendation for research, see the rationale section on Dravet syndrome.

Full details of the evidence and the committee's discussion are in evidence review K: effectiveness of antiseizure therapies in the treatment of Dravet syndrome.

For a short explanation of why the committee made this recommendation for research, see the rationale section on Lennox–Gastaut syndrome.

Full details of the evidence and the committee's discussion are in evidence review L: effectiveness of antiseizure therapies in the treatment of Lennox-Gastaut syndrome.

For a short explanation of why the committee made this recommendation for research, see the rationale section on infantile spasms syndrome.

Full details of the evidence and the committee's discussion are in evidence review P: effectiveness of antiseizure therapies for infantile spasms.

For a short explanation of why the committee made this recommendation for research, see the rationale section on epilepsy with myoclonic-atonic seizures (Doose syndrome).

Full details of the evidence and the committee's discussion are in evidence review R: effectiveness of antiseizure therapies for epilepsy with myoclonic-atonic seizures (Doose syndrome).

Source guidance details

Comes from guidance

Epilepsies in children, young people and adults

Number

NG217

Date issued

April 2022

Other details